The forecasted revenue for FY24 by Evoke Pharma is very close to the analyst estimates, suggesting that the company's financial performance is in line with market expectations. This alignment typically indicates a stable outlook for the company, neither significantly outperforming nor underperforming market expectations. Therefore, the short-term impact on the stock price is likely neutral, as the news may not significantly alter investor perceptions of the company's financial health or growth prospects.